Quijada-Álamo, Miguel <br/><br/>
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.  [electronic resource] 

 -  Leukemia  06 2020 
 - 1599-1612 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/s41375-020-0714-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Ataxia Telangiectasia Mutated Proteins--genetics<br/>CRISPR-Cas Systems<br/>Cell Line, Tumor<br/>Chromosome Deletion<br/>Chromosomes, Human, Pair 11--genetics<br/>Drug Synergism<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--genetics<br/>Mice<br/>Mutagenesis, Site-Directed--methods<br/>Mutation<br/>Phthalazines--pharmacology<br/>Piperazines--pharmacology<br/>Piperidines<br/>Poly (ADP-Ribose) Polymerase-1--antagonists & inhibitors<br/>Poly(ADP-ribose) Polymerase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-bcr--antagonists & inhibitors<br/>Pyrazoles--pharmacology<br/>Pyrimidines--pharmacology<br/>Xenograft Model Antitumor Assays